Ignite Creation Date:
2025-12-24 @ 11:35 PM
Ignite Modification Date:
2026-02-19 @ 2:50 PM
Study NCT ID:
NCT04225156
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-25
First Post:
2020-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016553', 'term': 'Purpura, Thrombocytopenic, Idiopathic'}], 'ancestors': [{'id': 'D011696', 'term': 'Purpura, Thrombocytopenic'}, {'id': 'D011693', 'term': 'Purpura'}, {'id': 'D001778', 'term': 'Blood Coagulation Disorders'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D057049', 'term': 'Thrombotic Microangiopathies'}, {'id': 'D013921', 'term': 'Thrombocytopenia'}, {'id': 'D001791', 'term': 'Blood Platelet Disorders'}, {'id': 'D000095542', 'term': 'Cytopenia'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D006470', 'term': 'Hemorrhage'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D012877', 'term': 'Skin Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000718373', 'term': 'efgartigimod alfa'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 101}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2020-06-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2026-03-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-24', 'studyFirstSubmitDate': '2020-01-06', 'studyFirstSubmitQcDate': '2020-01-08', 'lastUpdatePostDateStruct': {'date': '2025-09-25', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2020-01-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-03-11', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Frequency and severity of Adverse Events', 'timeFrame': 'Up to 60 weeks'}, {'measure': 'Frequency and severity of vital signs', 'timeFrame': 'Up to 60 weeks'}, {'measure': 'Frequency and severity of laboratory assessments', 'timeFrame': 'Up to 60 weeks'}], 'secondaryOutcomes': [{'measure': 'Extent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L.', 'timeFrame': 'Over the 52 weeks of treatment'}, {'measure': 'Percentage of patients with overall platelet count response defined as achieving a platelet count of ≥50×10^9/L on at least 4 occasions at any time during the 52-week treatment period.', 'timeFrame': 'Over the 52 weeks of treatment'}, {'measure': 'Mean change from baseline in platelet count at each visit.', 'timeFrame': 'Up to 60 weeks, at each visit'}, {'measure': 'For patients rolling-over from the ARGX-113-1801 trial with a platelet count of <30×10^9/L: time to response is defined as the time to achieve 2 consecutive platelet counts of ≥50×10^9/L', 'timeFrame': 'Up to 60 weeks, at each visit'}, {'measure': 'The percentage of weeks in the trial with platelet counts of ≥30×109/L and at least 20×10E9/L above baseline.', 'timeFrame': 'Over the 52 weeks of treatment'}, {'measure': 'In patients with baseline platelet count of <15×10E9/L in the current trial (ARGX-113-1803), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and at least 20×10E9/L above baseline.', 'timeFrame': 'Over the 52 weeks of treatment'}, {'measure': 'In patients with first exposure to efgartigimod: proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of at least 50×10^9/L for at least 4 of the 6 visits between week 19 and 24 of the trial.', 'timeFrame': 'Up to 5 weeks, between visit 19 and 24 of the trial'}, {'measure': 'In patients with first exposure to efgartigimod: proportion of patients in the overall population achieving platelet counts of at least 50x10^9/L for at least 6 of the 8 visits between week 17 and 24 of the trial.', 'timeFrame': 'Up to 7 weeks, between visit 17 and 24 of the trial'}, {'measure': 'Rate of receipt of rescue therapy (rescue per patient per month).', 'timeFrame': 'Up to 60 weeks, at each visit'}, {'measure': 'Reduction in concurrent ITP therapy.', 'timeFrame': 'Up to 60 weeks, at each visit'}, {'measure': 'Incidence and severity of the WHO-classified bleeding events.', 'timeFrame': 'Up to 60 weeks, at each visit'}, {'measure': 'Change from baseline in Patient reported Outcomes (FACIT-Fatigue) at planned visits.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Change from baseline in Patient reported Outcomes (Fact-Th6) at planned visits.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Change from baseline in Quality of Life (SF-36) at planned visits.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Incidence of anti-drug antibodies (ADA) to efgartigimod.', 'timeFrame': 'Up to 216 weeks'}, {'measure': 'Pharmacokinetic parameter of efgartigimod: serum concentration observed predose (Ctrough).', 'timeFrame': 'Up to 60 weeks'}, {'measure': 'Pharmacodynamics markers: total IgG.', 'timeFrame': 'Up to 60 weeks'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Primary Immune Thrombocytopenia']}, 'descriptionModule': {'briefSummary': 'This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n1. Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).\n2. Patients enrolled in the ARGX-113-1801 trial who completed the 24-weeks trial period.\n3. Women of childbearing potential must have a negative urine pregnancy test at baseline before trial medication (infusion) can be administered.\n4. Women of childbearing potential should use a highly effective or acceptable method of contraception during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month (as listed in the protocol)\n\n6\\. Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).\n\n7\\. Patient has completed a 52-week treatment period.\n\nExclusion criteria:\n\n1. Introduction or continuation of non-permitted medications during the ARGX-113-1801 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins or live/live-attenuated vaccines).\n2. Pregnant or lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing.\n3. Patients with known medical history of hypersensitivity to any of the ingredients of efgartigimod.\n4. Use of any other investigational drug or participation in any other investigational trial.'}, 'identificationModule': {'nctId': 'NCT04225156', 'acronym': 'ADVANCE+', 'briefTitle': 'A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).', 'organization': {'class': 'INDUSTRY', 'fullName': 'argenx'}, 'officialTitle': 'A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.', 'orgStudyIdInfo': {'id': 'ARGX-113-1803'}, 'secondaryIdInfos': [{'id': '2019-002101-21', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'efgartigimod', 'description': 'patients receiving efgartigimod', 'interventionNames': ['Biological: efgartigimod']}], 'interventions': [{'name': 'efgartigimod', 'type': 'BIOLOGICAL', 'otherNames': ['ARGX-113'], 'description': 'Intravenous infusion of efgartigimod', 'armGroupLabels': ['efgartigimod']}]}, 'contactsLocationsModule': {'locations': [{'zip': '20007', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'Investigator Site 0010045', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '34474', 'city': 'Ocala', 'state': 'Florida', 'country': 'United States', 'facility': 'Investigator Site 0010037', 'geoPoint': {'lat': 29.1872, 'lon': -82.14009}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'facility': 'Investigator Site 0010042', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Investigator Site 0010040', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'city': 'Vienna', 'country': 'Austria', 'facility': 'Investigator Site 0430002', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'city': 'Vienna', 'country': 'Austria', 'facility': 'Investigator Site 0430003', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'city': 'Brasschaat', 'country': 'Belgium', 'facility': 'Investigator Site 0320012', 'geoPoint': {'lat': 51.2912, 'lon': 4.49182}}, {'city': 'Bruges', 'country': 'Belgium', 'facility': 'Investigator Site 0320011', 'geoPoint': {'lat': 51.20892, 'lon': 3.22424}}, {'city': 'Turnhout', 'country': 'Belgium', 'facility': 'Investigator Site 0320014', 'geoPoint': {'lat': 51.32254, 'lon': 4.94471}}, {'city': 'Yvoir', 'country': 'Belgium', 'facility': 'Investigator Site 0320002', 'geoPoint': {'lat': 50.3279, 'lon': 4.88059}}, {'city': 'Pleven', 'country': 'Bulgaria', 'facility': 'Investigator Site 3590001', 'geoPoint': {'lat': 43.41791, 'lon': 24.61666}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Investigator Site 3590002', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Brno', 'country': 'Czechia', 'facility': 'Investigator Site 4200001', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'city': 'Olomouc', 'country': 'Czechia', 'facility': 'Investigator Site 4200008', 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}}, {'city': 'Ostrava', 'country': 'Czechia', 'facility': 'Investigator Site 4200006', 'geoPoint': {'lat': 49.83465, 'lon': 18.28204}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Investigator Site 4200007', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Créteil', 'country': 'France', 'facility': 'Investigator Site 0330009', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'city': 'Montpellier', 'country': 'France', 'facility': 'Investigator Site 0330018', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'city': 'Pessac', 'country': 'France', 'facility': 'Investigator Site 0330008', 'geoPoint': {'lat': 44.80565, 'lon': -0.6324}}, {'city': 'Périgueux', 'country': 'France', 'facility': 'Investigator Site 0330016', 'geoPoint': {'lat': 45.18691, 'lon': 0.71439}}, {'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Investigator site 9950007', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Investigator site 9950008', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Investigator site 9950009', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Investigator site 9950011', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'Investigator site 9950012', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Investigator Site 0490010', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'city': 'Essen', 'country': 'Germany', 'facility': 'Investigator Site 0490008', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'city': 'Budapest', 'country': 'Hungary', 'facility': 'Investigator Site 0360004', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Investigator Site 0360006', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'city': 'Győr', 'country': 'Hungary', 'facility': 'Investigator Site 0360015', 'geoPoint': {'lat': 47.68333, 'lon': 17.63512}}, {'city': 'Nyíregyháza', 'country': 'Hungary', 'facility': 'Investigator Site 0360010', 'geoPoint': {'lat': 47.95539, 'lon': 21.71671}}, {'city': 'Szombathely', 'country': 'Hungary', 'facility': 'Investigator Site 0360014', 'geoPoint': {'lat': 47.23088, 'lon': 16.62155}}, {'city': 'Milan', 'country': 'Italy', 'facility': 'Investigator Site 0390014', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'city': 'Monza', 'country': 'Italy', 'facility': 'Investigator Site 0390020', 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}}, {'city': 'Novara', 'country': 'Italy', 'facility': 'Investigator Site 0390015', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'city': 'Ravenna', 'country': 'Italy', 'facility': 'Investigator Site 0390010', 'geoPoint': {'lat': 44.41344, 'lon': 12.20121}}, {'city': 'Reggio Calabria', 'country': 'Italy', 'facility': 'Investigator Site 0390011', 'geoPoint': {'lat': 38.11047, 'lon': 15.66129}}, {'city': 'Reggio Emilia', 'country': 'Italy', 'facility': 'Investigator Site 0390018', 'geoPoint': {'lat': 44.69825, 'lon': 10.63125}}, {'city': 'Rimini', 'country': 'Italy', 'facility': 'Investigator Site 0390019', 'geoPoint': {'lat': 44.05755, 'lon': 12.56528}}, {'city': 'Siena', 'country': 'Italy', 'facility': 'Investigator Site 0390009', 'geoPoint': {'lat': 43.31822, 'lon': 11.33064}}, {'city': 'Trieste', 'country': 'Italy', 'facility': 'Investigator Site 0390016', 'geoPoint': {'lat': 45.64953, 'lon': 13.77678}}, {'city': 'Hirakata', 'country': 'Japan', 'facility': 'Investigator Site 0810015', 'geoPoint': {'lat': 34.81352, 'lon': 135.64914}}, {'city': 'Hiroshima', 'country': 'Japan', 'facility': 'Investigator Site 0810010', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'city': 'Iruma', 'country': 'Japan', 'facility': 'Investigator Site 0810017', 'geoPoint': {'lat': 35.818, 'lon': 139.368}}, {'city': 'Kashiwa', 'country': 'Japan', 'facility': 'Investigator Site 0810022', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}, {'city': 'Maebashi', 'country': 'Japan', 'facility': 'Investigator Site 0810018', 'geoPoint': {'lat': 36.4, 'lon': 139.08333}}, {'city': 'Niigata', 'country': 'Japan', 'facility': 'Investigator Site 0810021', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}, {'city': 'Sapporo', 'country': 'Japan', 'facility': 'Investigator Site 0810014', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'city': 'Shibukawa', 'country': 'Japan', 'facility': 'Investigator Site 0810016', 'geoPoint': {'lat': 36.48333, 'lon': 139.0}}, {'city': 'Shimotsuke', 'country': 'Japan', 'facility': 'Investigator Site 0810023', 'geoPoint': {'lat': 36.41323, 'lon': 139.86622}}, {'city': 'Rotterdam', 'country': 'Netherlands', 'facility': 'Investigator Site 0310005', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'city': 'The Hague', 'country': 'Netherlands', 'facility': 'Investigator Site 0310006', 'geoPoint': {'lat': 52.07667, 'lon': 4.29861}}, {'city': 'Gdansk', 'country': 'Poland', 'facility': 'Investigator Site 0480012', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'city': 'Katowice', 'country': 'Poland', 'facility': 'Investigator Site 0480013', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'city': 'Lodz', 'country': 'Poland', 'facility': 'Investigator Site 0480011', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'city': 'Lublin', 'country': 'Poland', 'facility': 'Investigator Site 0480014', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'city': 'Nowy Sącz', 'country': 'Poland', 'facility': 'Investigator Site 0480026', 'geoPoint': {'lat': 49.62177, 'lon': 20.69705}}, {'city': 'Kaluga', 'country': 'Russia', 'facility': 'Investigator Site 0070006', 'geoPoint': {'lat': 54.53063, 'lon': 36.27}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'Investigator Site 0070008', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Petrozavodsk', 'country': 'Russia', 'facility': 'Investigator Site 0070007', 'geoPoint': {'lat': 61.78491, 'lon': 34.34691}}, {'city': 'Rostov-on-Don', 'country': 'Russia', 'facility': 'Investigator Site 0070013', 'geoPoint': {'lat': 47.21997, 'lon': 39.70769}}, {'city': 'Syktyvkar', 'country': 'Russia', 'facility': 'Investigator Site 0070015', 'geoPoint': {'lat': 61.66393, 'lon': 50.8163}}, {'city': 'Tula', 'country': 'Russia', 'facility': 'Investigator Site 0070012', 'geoPoint': {'lat': 54.19609, 'lon': 37.61822}}, {'city': 'Ufa', 'country': 'Russia', 'facility': 'Investigator Site 0070010', 'geoPoint': {'lat': 54.74306, 'lon': 55.96779}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': 'Investigator Site 0340006', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': 'Investigator Site 0340007', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Investigator Site 0340009', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Investigator Site 0340014', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Palma de Mallorca', 'country': 'Spain', 'facility': 'Investigator Site 0340012', 'geoPoint': {'lat': 39.56939, 'lon': 2.65024}}, {'city': 'Pozuelo de Alarcón', 'country': 'Spain', 'facility': 'Investigator Site 0340015', 'geoPoint': {'lat': 40.43293, 'lon': -3.81338}}, {'city': 'Seville', 'country': 'Spain', 'facility': 'Investigator Site 0340013', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'Valencia', 'country': 'Spain', 'facility': 'Investigator Site 0340004', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Valencia', 'country': 'Spain', 'facility': 'Investigator Site 0340011', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900003', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900006', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'city': 'Ankara', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900015', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'city': 'Edirne', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900016', 'geoPoint': {'lat': 41.67719, 'lon': 26.55597}}, {'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900013', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900004', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'city': 'Mersin', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900010', 'geoPoint': {'lat': 36.81196, 'lon': 34.63886}}, {'city': 'Sakarya', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900007', 'geoPoint': {'lat': 39.50333, 'lon': 32.07583}}, {'city': 'Samsun', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900009', 'geoPoint': {'lat': 41.27976, 'lon': 36.3361}}, {'city': 'Tekirdağ', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900017', 'geoPoint': {'lat': 40.9781, 'lon': 27.51101}}, {'city': 'Trabzon', 'country': 'Turkey (Türkiye)', 'facility': 'Investigator Site 0900019', 'geoPoint': {'lat': 41.005, 'lon': 39.72694}}, {'city': 'Mykolaiv', 'country': 'Ukraine', 'facility': 'Investigator Site 3800006', 'geoPoint': {'lat': 49.52659, 'lon': 23.98138}}, {'city': 'London', 'country': 'United Kingdom', 'facility': 'Investigator Site 0440008', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Southampton', 'country': 'United Kingdom', 'facility': 'Investigator Site 0440012', 'geoPoint': {'lat': 50.90395, 'lon': -1.40428}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'argenx', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}